In vitro killing of parenteral beta-lactams against standard and high mocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae

被引：62
作者：
Burgess, DS [1 ]
Hall, RG
机构：
[1] Univ Texas, Coll Pharm, Austin, TX 78712 USA
[2] Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78284 USA
[3] Texas Tech Univ, Sch Pharm, Hlth Sci Ctr, Dept Pharm Practice, Amarillo, TX USA
[4] N Texas Vet Healthcare Syst, Dept Pharm, Dallas, TX USA
来源：
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE | 2004年 / 49卷 / 01期
关键词：
D O I：
10.1016/j.diagmicrobio.2003.11.007
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Minimum inhibitory Concentrations and time-kill curves were performed against 8 Klebsiella pneumoniae (4 non-extended-spectrum beta-lactamase[ESBL] and 4 ESBL) for piperacillin/tazobactam (40/5 mug/mL), cefepime (20 mug/mL), and meropenem (4 mug/mL) by using a standard and high inocula. Imipenem was evaluated only at the standard inoculum for the non-ESBL and ESBL isolates. Samples were withdrawn at 7 predetermined time-points over 24 hours and plated on trypticase soy agar plates. Minimum inhibitory concentrations were: piperacilliii/tazobactaiii 4 to 8 mug/mL (ESBL and non-ESBL), cefepime 1 to 2 mug/mL (ESBL) and 0.06 to 0.125 mug/mL (non-ESBL), imipenem 0.125 to 0.25 mug/mL (ESBL and non-ESBL), and meropenem 0.03 to 0.06 mug/mL (ESBL and non-ESBL). Each antibiotic reached and maintained bactericidal killing (greater than or equal to3 log killing) for 24 hours against all non-ESBL isolates for both the standard and high inoculum. Cefepime, imipenem, and meropenem showed the same bactericidal activity against each ESBL isolate at the standard inoculum, whereas piperacillin/tazobactam showed bactericidal killing against only 1 ESBL isolate. At the high inoculum, cefepime and piperacillin/tazobactam were unable to maintain bactericidal activity against any of the ESBL isolates. Only meropenem was able to maintain bactericidal killing over 24 hours against the ESBL isolates at the high inoculum. In summary, meropenem and imipenem maintained bactericidal activity against non-ESBL and ESBL K. pneumoniae irrespective of the inoculum size. While piperacillin/tazobactam and cefepime are bactericidal against non-ESBL K. pneumoniae, their activity against ESBL K. pneumoniae is limited and based on the size of the inoculum. Until more data are available, piperacillin/tazobactam and cefepime should not be used for the treatment of ESBL K. pneumoniae. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码：41 / 46
页数：6
相关论文
共 29 条
[1]   Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum β-lactamases [J].
Bedenic, B ;
Beader, N ;
Zagar, Z .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (11) :626-635
[2]   Extended-spectrum β-lactamases in the 21st century:: Characterization, epidemiology, and detection of this important resistance threat [J].
Bradford, PA .
CLINICAL MICROBIOLOGY REVIEWS, 2001, 14 (04) :933-951
[3]   Clinical and microbiologic analysis of a hospital's extended-spectrum β-lactamase-producing isolates over a 2-year period [J].
Burgess, DS ;
Hall, RG ;
Lewis, JS ;
Jorgensen, JH ;
Patterson, JE .
PHARMACOTHERAPY, 2003, 23 (10) :1232-1237
[4]   Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing [J].
Burgess, DS ;
Waldrep, T .
CLINICAL THERAPEUTICS, 2002, 24 (07) :1090-1104
[5]   Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion [J].
Burgess, DS ;
Hastings, RW ;
Hardin, TC .
CLINICAL THERAPEUTICS, 2000, 22 (01) :66-75
[6]   MULTIPLE-DOSE PHARMACOKINETICS OF IMIPENEM-CILASTATIN [J].
DRUSANO, GL ;
STANDIFORD, HC ;
BUSTAMANTE, C ;
FORREST, A ;
RIVERA, G ;
LESLIE, J ;
TATEM, B ;
DELAPORTAS, D ;
MACGREGOR, RR ;
SCHIMPFF, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 26 (05) :715-721
[7]   In vitro time-kill curves of cefepime and cefpirome combined with amikacin, gentamicin or ciprofloxacin against Klebsiella pneumoniae producing extended-spectrum beta-lactamase [J].
Elkhaili, H ;
Kamili, N ;
Linger, L ;
Leveque, D ;
Pompei, D ;
Monteil, H ;
Jehl, F .
CHEMOTHERAPY, 1997, 43 (04) :245-253
[8]   ACTIVITIES OF BETA-LACTAM ANTIBIOTICS AGAINST ESCHERICHIA-COLI STRAINS PRODUCING EXTENDED-SPECTRUM BETA-LACTAMASES [J].
JACOBY, GA ;
CARRERAS, I .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :858-862
[9]   IN-VITRO ACTIVITIES OF VARIOUS BETA-LACTAM ANTIMICROBIAL AGENTS AGAINST CLINICAL ISOLATES OF ESCHERICHIA-COLI AND KLEBSIELLA SPP RESISTANT TO OXYIMINO CEPHALOSPORINS [J].
JETT, BD ;
RITCHIE, DJ ;
REICHLEY, R ;
BAILEY, TC ;
SAHM, DF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1187-1190
[10]   Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections [J].
Johnson, DM ;
Biedenbach, DJ ;
Jones, RN .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 43 (01) :49-60
123